Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021
About this study
Although impressive progress has been made with this new therapeutic strategy, only a proportion of patients achieve a complete and sustained response. Studies have already identified predictive factors of treatment response that are now widely recognized. In this study, the investigators aim to identify other response factors not yet evaluated in the literature.
- Condition
- Stage III Melanoma
- Sponsor
- University Hospital, Strasbourg, France
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 7
- Minimum age: 18 years
- Study condition: Stage III Melanoma
- Age ≥ 18 years;
- Unresectable stage III or stage IV melanoma according to the AJCC classification - 8th edition;
- Curative immunotherapy treatment (anti-PD-1 and/or anti-CTLA-4);
- Treatment and follow-up at the Dermatology Department of the Strasbourg University Hospitals;
- Immunotherapy initiated between January 1, 2013, and December 31, 2021.
Exclusion 5
- Primary choroidal melanoma;
- Adjuvant-intent immunotherapy;
- Less than 3 months of follow-up after the start of immunotherapy;
- Change of treatment before the first reassessment;
- Treatment and follow-up at a department other than the Dermatology Department of the Strasbourg University Hospitals.
Where
1 site, 1 recruiting
Service de dermatologie - Réanimation - CHU de Strasbourg - France
Strasbourg, France
Contact
-
Cédric LENORMAND, MD
33 3 88 11 66 27 cedric.lenormand@chru-strasbourg.fr
Potential match only. Final eligibility is determined by the study team.